Real-World Anti-VEGF Results Fall Short in Macular Edema

Source: Medscape

Real-world patients with diabetic macular edema treated with anti–vascular endothelial growth factor (VEGF) do not do as well as similar patients in clinical trials, according to an analysis of medical records from nearly 6000 patients seen at ophthalmology practices in the United States, according to a Medscape report.

"The patients had about eight injections, and they gained six letters at 1 year, so from that perspective, it's good news," said Thomas A. Ciulla, MD, MBA, from the Indiana School of Medicine in Indianapolis, and an employee of Spark Therapeutics in Philadelphia, Pennsylvania.

Read the full article here.

Related Content